quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:58:07·90d
SECFiling
Taysha Gene Therapies Inc. logo

SEC Form 144 filed by Taysha Gene Therapies Inc.

TSHA· Taysha Gene Therapies Inc.
Health Care
Original source

Companies

  • TSHA
    Taysha Gene Therapies Inc.
    Health Care

Recent analyst ratings

  • Oct 21UpdateRaymond James$13.00
  • Jul 11UpdateBofA Securities$8.00
  • Jun 27UpdateBMO Capital Markets$5.00
  • Apr 9UpdatePiper Sandler$9.00
  • Feb 1UpdateJefferies$1.50
  • Jan 27UpdateMorgan Stanley$3.00

Related

  • SEC2d
    SEC Form DEFA14A filed by Taysha Gene Therapies Inc.
  • SEC2d
    SEC Form DEF 14A filed by Taysha Gene Therapies Inc.
  • INSIDER10d
    SEC Form 4 filed by Nagendran Sukumar
  • SEC13d
    SEC Form 144 filed by Taysha Gene Therapies Inc.
  • PR21d
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • SEC36d
    SEC Form 10-K filed by Taysha Gene Therapies Inc.
  • SEC36d
    Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
  • PR36d
    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022